Skip to main content
BL Pharmtech Corp. logo

BL Pharmtech Corp. — Investor Relations & Filings

Ticker · 065170 ISIN · KR7065170003 KO Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2024-03-20 Audit Report / Informat…
Country KR South Korea
Listing KO 065170

About BL Pharmtech Corp.

http://www.blpharmtech.com/

BL Pharmtech Corp. is a healthcare company that manufactures, distributes, and sells health functional foods, dietary supplements, and nutraceuticals. The company's portfolio also includes cosmetics, food additives, and pharmaceuticals. A significant part of its operations is dedicated to biotechnology and bio-pharmaceutical research and development. Through its Daedeok Research Institute and in collaboration with subsidiaries BL Melanys and BL Science, the company partners with academic institutions, including KAIST and Columbia University Medical Center, to advance its research initiatives.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'BL Pharmtech' (주식회사 비엘팜텍) for the fiscal year ending December 31, 2023. It includes the independent auditor's report from Samil PricewaterhouseCoopers, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a comprehensive financial audit document, not an annual report (10-K) which would typically include management discussion and analysis (MD&A) and broader corporate governance sections, nor is it a short announcement. Therefore, it is classified as an Audit Report. FY 2023
2024-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial data, audit opinions, and key financial metrics (capital impairment, operating losses) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement regarding the submission of the audit report rather than the full, multi-page audited financial statement document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically a stock purchase agreement (주식 양수도계약) by a major shareholder. This type of filing is used to notify the market of significant changes in shareholding levels (crossing thresholds) and falls under the 'Major Shareholding Notification' category.
2024-03-19 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by a major shareholder (Park Young Chul) in BL Pharmtech, including the number of shares, percentage of ownership, and the purpose of the holding (influencing management). This falls under the category of Major Shareholding Notification.
2024-03-19 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by BIOPHARMTECH. It outlines the date, location, agenda items (financial statement approval, director and auditor appointments, and remuneration limits), and details of the candidates for board positions. This document is a standard proxy solicitation material provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2024-03-13 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for BL Pharmtech. It contains the agenda for the 29th Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. It also includes management's business report and financial statements (balance sheet, income statement, etc.) as reference materials for shareholders. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on agenda items at the upcoming meeting.
2024-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.